Skip to main content

Table 2 Clinicopathological data of breast cancer patients of validation cohort #2

From: Overexpression of circulating MiR-30b-5p identifies advanced breast cancer

Clinicopathological featuresLocalized BrCAdvanced BrC
Patients (n)2025
Age median (range)61 (39–71)53 (35–82)
Molecular subtypea (%)
 Luminal A-Like7 (35.0)2 (8.0)
 Luminal B-Like13 (65.0)16 (64.0)
 HER2-enriched5 (20.0)
 Basal-like2 (8.0)
Histological type (%)
 Invasive carcinoma of NST17 (85.0)18 (72.0)
 Invasive lobular carcinoma2 (10.0)4 (16.0)
 Other special subtype carcinoma2 (8.0)
 Mixed type carcinoma1 (5.0)1 (4.0)
Grade (%)
 G14 (20.0)
 G29 (45.0)19 (76.0)
 G37 (35.0)6 (24.0)
ER receptor status (%)
 Positive20 (100.0)18 (72.0)
 Negative7 (28.0)
PR receptor status (%)
 Positive20 (100.0)14 (56.0)
 Negative11 (44.0)
HER2 receptor status (%)
 Positive4 (20.0)11 (44.0)
 Negative16 (80.0)14 (56.0)
T Stage (%)
 T120 (100.0)3 (12.0)
 T211 (44.0)
 T35 (20.0)
 T46 (24.0)
N Stage (%)
 N020 (100.0)
 N14 (16.0)
 N2
 N320 (80.0)
 Nx1 (4.0)
Stage (%)
 IA20 (100.0)n.a.
 IIICn.a.13 (52.0)
 IVn.a.12 (48.0)
  1. BrC breast cancer, ER estrogen receptor, G grade, HER2 human epidermal growth factor receptor 2, n.a. not applicable, NST no special type, PR progesterone receptor
  2. aAssessed by immunohistochemistry